Latest news

• Lilly boosted by survival data for key growth drug Verzenio

  New results from the MONARCH 2 trial have shown that the CDK4/6 inhibitor achieved a statistically significant improvement in overall survival in pre-, peri- and post-menopausal women with advanced, ... However, shortly after the top-line data were

• NICE nod for Lilly’s breast cancer drug Verzenio via CDF

  Helps Lilly drug in pursuit of Ibrance and Kisqali. Thousands of women with advanced breast cancer could get access to treatment with Eli Lilly’s CDK 4/6 inhibitor Verzenio, after ... $6bn product at peak by EvaluatePharma – as well as Novartis’

• NICE gives Lilly’s Verzenios chance to compete with rivals

  CDK4/6 inhibitor class. ... Around 46, 000 women are diagnosed with breast cancer each year in England and Wales, of whom around 8, 000 would be eligible for treatment with a CDK4/6 inhibitor.

• CHMP backs Sanofi’s all-oral sleeping sickness drug

  Among these, Novartis’ CDK4/6 inhibitor Kisqali (ribociclib) was recommended for the treatment of women with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer in combination with fulvestrant

• Novartis claims a rare win at ESMO for PI3K inhibitor class

  16%. Alpelisib was also fairly well tolerated in the 572-patient study, which involved patients whose disease had progressed after earlier treatment with an aromatase inhibitor with or without a ... 6 inhibitor, a newer drug group which includes